Now, scientists at the Max Planck Institute of Colloids and Interfaces in Potsdam have demonstrated that C. difficile bacteria can be recognized by specific sugars on their surface. Antibodies that attack the sugars can be used to treat infected animals and save their lives. The bacterium Clostridium difficile invades up to 40% of patients in hospitals, causes serious infections that require harsh treatment with antibiotics and kills about 15.000 people in Europe annually. The results reported recently in the journal Nature Communications are the basis for further clinical development.
Hospital-acquired infections are a rapidly increasing problem in industrialized countries as more antibiotic-resistant bacteria evolve. The anaerobic bacterium Clostridium difficile has emerged as a major cause of disease in hospitals and long-term care facilities where up to 40% of inpatients are infected.
The bacterium blooms in the gut when protective bacteria are diminished by antibiotics. Symptoms include diarrhea, dehydration, intestinal inflammation and death in severe cases.
As antibiotic resistance continues to rise, novel therapies are needed urgently. In the US alone, over 250.000 C. difficile infections annually are responsible for at least 15.000 deaths and medical expenses of over one billion dollars.
Researchers at the Max Planck Institute of Colloids and Interfaces now report monoclonal antibodies against the sugars on the surface of C. difficile as a novel antibacterial therapy. Chemically synthesized sugars that resemble those covering the bacterium were used to generate monoclonal antibodies that specifically recognize and kill any pathogen carrying the motif.
Since the sugar motif called PS-I is found on a wide range of C. difficile strains, the novel therapeutic is expected to be very broadly applicable. Another advantage is that other bacteria of the gut remain intact and lower the likelihood of re-infection by C. difficile that is a common result of antibiotic treatment.
The results reported in Nature Communications are the basis for ongoing efforts to develop novel therapeutics. “This is a great example how basic research on fundamental aspects of the human immune response results in therapeutic candidates that will help fight one of the most devastating hospital-acquired infections” says Prof. Peter Seeberger, the senior author of the study.
The team at the Max Planck Institute of Colloids and Interfaces in Potsdam continues to work with Vaxxilon AG (Reinach, Switzerland) to advance novel carbohydrate vaccines. Vaxxilon has licensed certain intellectual property rights to a portfolio of vaccine candidates targeting multiple infectious agents, including C. difficile.
Katja Schulze | Max-Planck-Institut für Kolloid- und Grenzflächenforschung
A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences